Literature DB >> 10720031

Activin effects on neoplastic proliferation of human pituitary tumors.

D C Danila1, W J Inder, X Zhang, J M Alexander, B Swearingen, E T Hedley-Whyte, A Klibanski.   

Abstract

Factors underlying growth regulation in human pituitary tumors are largely unknown. Activin functions as an antiproliferative cytokine in a number of cell types and is endogenously expressed in normal and neoplastic human pituicytes. We investigated the effect of activin on proliferation in 16 clinically nonfunctioning pituitary adenomas in primary culture. Treatment for 24 h with activin (0-10 ng/mL) significantly inhibited cell proliferation in 5 tumors (P < 0.05), as determined by [3H]thymidine incorporation. In 9 tumors, we studied regulation of the cyclin-dependent kinase inhibitor p21WAF1/cip1 as a potential activin mediator. In tumors with activin-inhibited proliferation, p21WAF1/cip1 gene expression was up-regulated after 4 h in a dose-dependent manner (0-100 ng/mL). We also investigated tumor expression of follistatin messenger ribonucleic acid, an activin-binding protein with two isoforms of different potencies. In contrast to normal pituitary tissue, only four tumors expressed both follistatin isoforms, and three tumors expressed only the less potent form. Tumors in which activin induced antiproliferative responses showed diminished or no follistatin messenger ribonucleic acid expression compared to normal pituitary. These data indicate that activin has an antiproliferative effect in a subgroup of human pituitary tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720031     DOI: 10.1210/jcem.85.3.6473

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Localization of inhibin/activin subunits in normal pituitary and in pituitary adenomas.

Authors:  S Uccella; S La Rosa; A Genasetti; C Capella
Journal:  Pituitary       Date:  2000-11       Impact factor: 4.107

2.  Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin.

Authors:  Barbara H Jung; Stayce E Beck; Jennifer Cabral; Eddy Chau; Betty L Cabrera; Antonio Fiorino; E Julieta Smith; Melanie Bocanegra; John M Carethers
Journal:  Gastroenterology       Date:  2006-11-16       Impact factor: 22.682

3.  The Local Control of the Pituitary by Activin Signaling and Modulation.

Authors:  Louise M Bilezikjian; Wylie W Vale
Journal:  Open Neuroendocrinol J       Date:  2011-01-01

Review 4.  Cell-type specific modulation of pituitary cells by activin, inhibin and follistatin.

Authors:  Louise M Bilezikjian; Nicholas J Justice; Alissa N Blackler; Ezra Wiater; Wylie W Vale
Journal:  Mol Cell Endocrinol       Date:  2012-02-04       Impact factor: 4.102

5.  Selective inhibition of cell growth by activin in SNU-16 cells.

Authors:  Young-Il Kim; Hee-Joo Lee; Inkoo Khang; Byung-Nam Cho; Ha Kyu Lee
Journal:  World J Gastroenterol       Date:  2006-05-21       Impact factor: 5.742

6.  FoxL2 and Smad3 coordinately regulate follistatin gene transcription.

Authors:  Amy L Blount; Karsten Schmidt; Nicholas J Justice; Wylie W Vale; Wolfgang H Fischer; Louise M Bilezikjian
Journal:  J Biol Chem       Date:  2008-12-23       Impact factor: 5.157

7.  Activin A balance regulates epithelial invasiveness and tumorigenesis.

Authors:  Grégoire F Le Bras; Holli A Loomans; Chase J Taylor; Frank L Revetta; Claudia D Andl
Journal:  Lab Invest       Date:  2014-07-28       Impact factor: 5.662

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.